Massive migraine study aims to unlock secrets of chronic head pain
NCT ID NCT07163416
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This large observational study will follow over 2,000 adults with migraine in Italy for two years. Researchers will collect data on symptoms, treatments, and healthcare use to better understand how migraine evolves and how patients are managed. The goal is to improve diagnosis and care pathways for people with episodic and chronic migraine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could reveal better ways to diagnose and treat migraine, improving patient care and reducing healthcare costs.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test new therapies. Results depend on accurate patient reporting and may not apply outside Italy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Head, Irccs San Raffaele Roma S.r.l. - Unità per la cura e la ricerca su cefalee e dolore - Dipartimento di Neurologia, Via di Val di Cannuta 250, 00166 Roma (RM) - Italy
RECRUITINGRoma, Roma, 00166, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted botox shot quiet the Brain's pain center for chronic migraine?
- Could a symptom registry unmask hidden migraine variants?
- Melatonin may double up against childhood migraines
- Online sleep therapy may ease migraines in teens
- Scientists aim to forecast migraine pain using wearable sensors and early symptoms
- Migraine drug AJOVY under Real-World safety spotlight